n-n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium and Carcinoma--Hepatocellular

The role of positron emission tomography/computed tomography (PET/CT) in hepatocellular carcinoma (HCC) management is not clearly defined. Our objective was to analyze the utility of dual-PET/CT (. Between January 2011 and April 2019, 168 consecutive HCC patients with available baseline dual-PET/CT imaging data were retrospectively analyzed. To identify potential refinement criteria for surgically-treated patients, survival Kaplan-Meier curves of various standard-of-care and dual-PET/CT baseline parameters were estimated. Finally, multivariate cox proportional hazard ratios of the most relevant clinico-biological and/or PET parameters were estimated.

Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Choline; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies

Transarterial radioembolization (TARE) is widely used for the treatment of hepatocellular carcinoma (HCC), but early treatment response can be very difficult to assess. The aim was to evaluate 18F-fluorocholine PET/computed tomography (CT) to assess the treatment response in patients with intermediate or locally advanced HCC.. Between March 2019 and July 2020, nine HCC patients treated with TARE, who underwent PET/CT at baseline and 1 month after treatment, were enrolled. The maximum, mean (SUVmean), and peak (SUVpeak) standardized uptake value (SUV), SUV normalized by lean body mass (SUL), and total lesion glycolysis (TLG) were measured. Statistical analysis used the Mann-Whitney test to evaluate the differences in parameters between responders (partial and complete response) and nonresponders (stable or progressive disease) at the 6-month follow-up, according to the modified Response Evaluation Criteria in Solid Tumors.. Three patients were nonresponders (progressive disease and stable disease) and six were responders. Delta SUVmean, delta SUL, and delta TLG could predict an early response (P = 0.02, P = 0.04, and P = 0.02, respectively). None of the pre-therapeutic parameters were correlated with the response. Post-therapeutic SUL, SUVmean, TLG, and SUVpeak were also predictive of the response.. Our preliminary results showed that changes in certain metabolic parameters (from baseline PET to 1-month PET) are predictive of the response to TARE in HCC (Delta SUVmean, delta TLG, and delta SUL). The absence of post-treatment inflammation could lead to a better prediction than MRI evaluation. This study suggests that 1-month 18F-choline PET/CT could modify the clinical management predicting responders.Video Abstract: http://links.lww.com/NMC/A193.

Topics: Adult; Aged; Carcinoma, Hepatocellular; Choline; Embolization, Therapeutic; Glycolysis; Humans; Liver Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography

We present a case of a 68-year-old woman undergoing 18F-choline PET/CT due to a history of hepatocellular cancer treated with multimodal therapies and with a rapid increase in α-fetoprotein. 18F-Choline PET/CT showed multiple uptakes in the skeletal muscles compatible with the recurrence of disease. The interpretation of 18F-choline PET/CT in this cancer should be careful and discussed in a multidisciplinary team.

Topics: Aged; Carcinoma, Hepatocellular; Choline; Humans; Liver Neoplasms; Male; Muscle, Skeletal; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals

To compare the performance of the quantitative analysis of the hepatobiliary phase (HBP) tumor enhancement in gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI and of dual-tracer 18F-FDG and 18F-fluorocholine (FCH) PET/CT for the prediction of tumor aggressiveness and recurrence-free survival (RFS) in resectable hepatocellular carcinoma (HCC).. This retrospective, IRB approved study included 32 patients with 35 surgically proven HCCs. All patients underwent Gd-BOPTA-enhanced MRI including delayed HBP images, 18F-FDG PET/CT, and (for 29/32 patients) 18F-FCH PET/CT during the 2 months prior to surgery. For each lesion, the lesion-to-liver contrast enhancement ratio (LLCER) on MRI HBP images and the SUV. HBP tumor enhancement after Gd-BOPTA injection may help identify aggressive HCC pathological features, and patients with reduced recurrence-free survival after surgical resection.. • In patients with resectable HCC, the quantitative analysis of the HBP tumor enhancement in Gd-BOPTA-enhanced MRI (LLCER) accurately identifies moderately-poorly differentiated and/or MVI-positive HCCs. • After surgical resection for HCC, patients with LLCER - 4.72% or less had significantly poorer recurrence-free survival than patients with LLCER superior to - 4.72%. • Gd-BOPTA-enhanced MRI with delayed HBP images may be suggested as part of pre-surgery workup in patients with resectable HCC.

Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Choline; Contrast Media; Disease-Free Survival; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Neoplasm Staging; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Recurrence; Retrospective Studies

Positron emission tomography (PET) using the cationic compound [

Topics: Adenoma, Liver Cell; Carcinoma, Hepatocellular; Choline; Diagnosis, Differential; Female; Fluorine Radioisotopes; HEK293 Cells; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Organic Cation Transport Proteins; Organic Cation Transporter 1; Positron-Emission Tomography; Tissue Distribution

Diagnosis of recurrent hepatocellular carcinoma (HCC) is sometimes challenging, especially when extrahepatic disease is present. Here, we report on a 49-year-old woman with a history of HCC who was referred to our institution with suspicion of tumor recurrence for further workup. Combined F-choline PET/CT revealed a soft tissue mass at the right thoracic wall highly consistent with HCC.

Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Choline; Female; Fluorine Radioisotopes; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Soft Tissue Neoplasms; Thoracic Wall; Tomography, X-Ray Computed

F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has variable efficacy in evaluating hepatocellular carcinoma. We present a case of a new oncologic imaging tracer fluoromethylcholine (FCH), which has visualized recurrent multifocal hepatoma in a patient with a poor FDG avid hepatic tumour. The lesions demonstrated on FCH PET correlated well with the findings on CT hepatic angiography.

Topics: Carcinoma, Hepatocellular; Choline; Female; Humans; Image Enhancement; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals